Daiichi Sankyo Company, Limited - Product Pipeline Review - 2016

  • ID: 3960484
  • Company Profile
  • 196 pages
  • Global Markets Direct
  • Daiichi Sankyo Co Ltd
1 of 5

FEATURED COMPANIES

  • Actelion Ltd
  • AstraZeneca Plc
  • Celgene Corporation
  • GlaxoSmithKline Plc
  • Novartis AG
  • MORE
Daiichi Sankyo Company, Limited - Product Pipeline Review - 2016

The report ‘Daiichi Sankyo Company, Limited - Product Pipeline Review - 2016’, provides an overview of the Daiichi Sankyo Company, Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Daiichi Sankyo Company, Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note - : Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

- The report provides a snapshot of the pipeline therapeutic landscape of Daiichi Sankyo Company, Limited
- The report provides overview of Daiichi Sankyo Company, Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Daiichi Sankyo Company, Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Daiichi Sankyo Company, Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy:

- Evaluate Daiichi Sankyo Company, Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Daiichi Sankyo Company, Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Daiichi Sankyo Company, Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Actelion Ltd
  • AstraZeneca Plc
  • Celgene Corporation
  • GlaxoSmithKline Plc
  • Novartis AG
  • MORE
Introduction

Daiichi Sankyo Company, Limited Snapshot

Daiichi Sankyo Company, Limited Overview

Key Facts

Daiichi Sankyo Company, Limited - Research and Development Overview

Key Therapeutic Areas

Daiichi Sankyo Company, Limited - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Daiichi Sankyo Company, Limited - Pipeline Products Glance

Daiichi Sankyo Company, Limited - Late Stage Pipeline Products

Daiichi Sankyo Company, Limited - Clinical Stage Pipeline Products

Daiichi Sankyo Company, Limited - Early Stage Pipeline Products

Daiichi Sankyo Company, Limited - Unknown Stage Pipeline Products

Daiichi Sankyo Company, Limited - Drug Profiles

A-503451A - Drug Profile

CS-1050 - Drug Profile

DC-159a - Drug Profile

denosumab - Drug Profile

DF-461 - Drug Profile

Drug to Inhibit IDH1 for Acute Myelocytic Leukemia and Glioma - Drug Profile

Drugs for Oncology, Cardiovascular and Metabolic Diseases - Drug Profile

DS-1040 - Drug Profile

DS-1093 - Drug Profile

DS-1123 - Drug Profile

DS-1501 - Drug Profile

DS-1558 - Drug Profile

DS-1971 - Drug Profile

DS-2330 - Drug Profile

DS-2969 - Drug Profile

DS-3032 - Drug Profile

DS-3201 - Drug Profile

DS-5141 - Drug Profile

DS-5272 - Drug Profile

DS-5573a - Drug Profile

DS-6051 - Drug Profile

DS-7080 - Drug Profile

DS-8108b - Drug Profile

DS-8201 - Drug Profile

DS-8273 - Drug Profile

DS-8500 - Drug Profile

DS-8895 - Drug Profile

DS-9001 - Drug Profile

DS-9231 - Drug Profile

edoxaban tosylate - Drug Profile

efatutazone - Drug Profile

esaxerenone - Drug Profile

etanercept biosimilar - Drug Profile

etirinotecan pegol - Drug Profile

hydromorphone hydrochloride - Drug Profile

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile

laninamivir - Drug Profile

mirogabalin besylate - Drug Profile

Monoclonal Antibodies for Undisclosed Indication - Drug Profile

Monoclonal Antibody Conjugate to Target HER2 for Breast Cancer - Drug Profile

nimotuzumab - Drug Profile

patritumab - Drug Profile

Pedopeptins to Inhibit LPS for Bacterial Infection - Drug Profile

PLX-51107 - Drug Profile

PLX-73086 - Drug Profile

PLX-7486 - Drug Profile

PLX-8394 - Drug Profile

PLX-9486 - Drug Profile

prasugrel hydrochloride - Drug Profile

Protein for Undisclosed Indication - Drug Profile

quizartinib dihydrochloride - Drug Profile

R-xxx - Drug Profile

Small Molecule for Cardiovascular-Metabolic Diseases - Drug Profile

Small Molecule for Respiratory Tract Infections - Drug Profile

Small Molecule for Tuberculosis - Drug Profile

Small Molecule to Agonize Liver X Receptor for Atherosclerosis - Drug Profile

Small Molecule to Agonize PPAR Alpha and PPAR Gamma for Metabolic Disorders - Drug Profile

Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile

Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections - Drug Profile

Small Molecule to Inhibit HSL for Dyslipidemia - Drug Profile

Small Molecule to Inhibit I-KappaB Kinase Beta for Rheumatoid Arthritis - Drug Profile

Small Molecule to Inhibit PDE4 for COPD - Drug Profile

Small Molecule to Inhibit PDE4B for Lung Inflammation - Drug Profile

Small Molecule to Inhibit Renin for Hypertension - Drug Profile

Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile

Small Molecules for Malaria - Drug Profile

Small Molecules for Multiple Neurodegenerative Diseases - Drug Profile

Small Molecules for Osteopenia and Osteoporosis - Drug Profile

Small Molecules to Agonize BRS-3 for Obesity - Drug Profile

Small Molecules to Agonize Pan PPAR for Multiple Sclerosis - Drug Profile

Small Molecules to Inhibit FATP1 for Undisclosed Indication - Drug Profile

Small Molecules to Inhibit FMS Kinase for Central Nervous System, Gastrointestinal, Immunology and Respiratory Diseases - Drug Profile

Small Molecules to Inhibit Nav1.7 for Pain - Drug Profile

Small Molecules to Inhibit p53-MDM2 Interaction for Cancer - Drug Profile

Sphaerimicin A - Drug Profile

SQ-641 - Drug Profile

Stem Cell Therapy for Congestive Heart Failure and Kawasaki Disease - Drug Profile

tivantinib - Drug Profile

U-31402 - Drug Profile

U-3771 - Drug Profile

U-3808 - Drug Profile

U3-1784 - Drug Profile

VN-0102 - Drug Profile

VN-0103 - Drug Profile

VN-0104 - Drug Profile

VN-0105 - Drug Profile

VN-100 - Drug Profile

Daiichi Sankyo Company, Limited - Pipeline Analysis

Daiichi Sankyo Company, Limited - Pipeline Products by Target

Daiichi Sankyo Company, Limited - Pipeline Products by Route of Administration

Daiichi Sankyo Company, Limited - Pipeline Products by Molecule Type

Daiichi Sankyo Company, Limited - Pipeline Products by Mechanism of Action

Daiichi Sankyo Company, Limited - Dormant Projects

Daiichi Sankyo Company, Limited - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Daiichi Sankyo Company, Limited - Company Statement

Daiichi Sankyo Company, Limited - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

List of Tables

Daiichi Sankyo Company, Limited, Key Facts

Daiichi Sankyo Company, Limited - Pipeline by Indication, 2016

Daiichi Sankyo Company, Limited - Pipeline by Stage of Development, 2016

Daiichi Sankyo Company, Limited - Monotherapy Products in Pipeline, 2016

Daiichi Sankyo Company, Limited - Combination Treatment Modalities in Pipeline, 2016

Daiichi Sankyo Company, Limited - Partnered Products in Pipeline, 2016

Daiichi Sankyo Company, Limited - Partnered Products/ Combination Treatment Modalities, 2016

Daiichi Sankyo Company, Limited - Out-Licensed Products in Pipeline, 2016

Daiichi Sankyo Company, Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016

Daiichi Sankyo Company, Limited - Pre-Registration, 2016

Daiichi Sankyo Company, Limited - Phase III, 2016

Daiichi Sankyo Company, Limited - Phase II, 2016

Daiichi Sankyo Company, Limited - Phase I, 2016

Daiichi Sankyo Company, Limited - Preclinical, 2016

Daiichi Sankyo Company, Limited - Discovery, 2016

Daiichi Sankyo Company, Limited - Unknown, 2016

Daiichi Sankyo Company, Limited - Pipeline by Target, 2016

Daiichi Sankyo Company, Limited - Pipeline by Route of Administration, 2016

Daiichi Sankyo Company, Limited - Pipeline by Molecule Type, 2016

Daiichi Sankyo Company, Limited - Pipeline Products by Mechanism of Action, 2016

Daiichi Sankyo Company, Limited - Dormant Developmental Projects,2016

Daiichi Sankyo Company, Limited - Discontinued Pipeline Products, 2016

Daiichi Sankyo Company, Limited, Subsidiaries

List of Figures

Daiichi Sankyo Company, Limited - Pipeline by Top 10 Indication, 2016

Daiichi Sankyo Company, Limited - Pipeline by Stage of Development, 2016

Daiichi Sankyo Company, Limited - Monotherapy Products in Pipeline, 2016

Daiichi Sankyo Company, Limited - Partnered Products in Pipeline, 2016

Daiichi Sankyo Company, Limited - Out-Licensed Products in Pipeline, 2016

Daiichi Sankyo Company, Limited - Pipeline by Top 10 Target, 2016

Daiichi Sankyo Company, Limited - Pipeline by Route of Administration, 2016

Daiichi Sankyo Company, Limited - Pipeline by Top 10 Molecule Type, 2016

Daiichi Sankyo Company, Limited - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Actelion Ltd
- Arena Pharmaceuticals, Inc.
- AstraZeneca Plc
- Bristol-Myers Squibb Company
- Celgene Corporation
- GlaxoSmithKline Plc
- Novartis AG
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll